Adaptive Biotechnologies (ADPT) 7 Nov 242024 Q3 Earnings call transcript

Good day, and welcome to Adaptive Biotechnologies Third Quarter Financial Results. [Operator Instructions] As a reminder, this call may be recorded. I would now like to turn the call over to Karina Calzadilla, Head of Investor Relations. Please go ahead.

Thank you, Michelle. Good afternoon, everyone. welcome Call. Adaptive to XXXX Third like Conference Earnings would you Biotechnologies to Quarter I we a today, the Earlier issued third results Adaptive's quarter for financial of 'XX. press release reporting is at release press The www.adaptivebiotech.com. available

referencing Investors a live has this will presentation We are our to to corporate webcast slide the conducting a posted of call, of and be section been that website.

the federal performance presentation. differ filings and will on forward-looking public business forward-looking statements current set as statements a of from the meaning depending our this of During today. the These in with Actual the other are within results events statements, future which forth financial and the materially securities make call, may SEC number reflect regarding and projections factors, perspective of of management company. in of today's listed future laws the management's

measures during from found In be release. non-GAAP addition, GAAP call, reconciliation in metrics to will non-GAAP can be and earnings a financial discussed our this

are CEO call Officer. the our and Robins, Financial Piskel, Kyle today Chief Joining and Co-Founder; Chad our

members for I'll over available call the Q&A. With Chad. management from Chad? turn to will that, Additional be

Karina. and Good for you us our Thanks, third call. earnings thank on quarter joining afternoon,

X, of on MRD on results quarter shown clear XX% the year-over-year, testament increased revenue Slide As top and a clinical both our pharma. and are execution strong line. continued for the bottom driven by

per sequentially, gapfill onetime decline $X,XXX that rate X year Operating further we cell of of reduction XX% which compared X catalysts approximately Medicare we months to a costs. Sequencing we spend ago. MRD first the significant gross secured burn the performance, MRD new cash period cost. leading in end previous in another efficiencies workflow, points from episode a a compared successfully Medicare revenue to guidance. of raising revenue a excluding to two, represents to margin X% increased coverage at $XXX as drive lymphoma. which of quarter previous million, are our same under executed reached will sample we prior lower last lower quarter, this the This XX% And our and XX% percentage rate versus year-to-date year increase X Due clonoSEQ mantle structure; is the One, strong had set ended year and our for for test, growth: our

remarks. year our annual are We operating share cash and will full Kyle our detailed reducing burn lowering expenses more in target. his

and with across and new observed year. volume, XX% and all the revenue the continues growth at of business followed DLBCL Other myeloma Multi ALL Now reached delivered let's clonoSEQ XX% clonoSEQ a such look largest at Test X. XX%, continue Slide be blood CLL delivered by marketed indicators XX% take tests a it trend the contributor X%. at increase key blood-based and record, new on prior testing to indications to grew launch in about versus and of data and HCPs Blood-based as expect ordering we to generate XX% community ordering positively. additional XX% sequentially represented we with respectively. contribution as tests, steady at versus XX% to XX% at MRD XX% XX% grew at representing indications. growth MCL. continue closer prior Tests overall clinical in grew year-over-year sequentially, and of accounts year, X%

quarter. achieved we for the important mentioned, As catalysts this business

are price Based seeing higher, payers. key updated at our $X,XXX determination test. of MolDX episode several per indications. noncontracted has for its we and executed with updated payers have rate, noncontracted momentum new or per gapfill $X,XXX Accordingly, clonoSEQ. see clonoSEQ to CMS covered we pricing for the new for positive gapfill we're rate other updated that on pleased to with new Medicare Recently, commercial the agreements test First, published this

with to working based accelerate are on payers our we increase negotiations this Additionally, to information. rates contracted

claims, fiscal ongoing from of ASP average coupled per represents reduce a to fiscal XXXX. cycle revenue optimize per an noncontracted year out-of-policy test test and year management and $XXX As on efforts This will with for reach increase anticipate we result, our approximately $X,XXX XXXX.

launch of coverage lymphoma, for morning, Second, clonoSEQ NHLs, MCL aggressive with of clonoSEQ experiencing mantle cell relapses. patients the it MCL. Medicare as MCL. reflects for patients in in follows MolDX another malignancy. that tool current valuable decision disease or MolDx's initiated gapfill is has coverage an updated of most lymphoma a X% about with form the announced the promotional accounting we we as With episode repeated MCL. We're have for expanded lymphoid This of monitoring role non-Hodgkin's in Of coverage place, reaffirms note, in and rate. pleased this activities clonoSEQ's now with structure

Lastly, a EMR drive key focus enhance and experience integration to to customer be growth. continues

our This including accounts, Epic quarter, we for completed customer, successfully X integrations largest ] Anderson. [ MD

integrations scheduled XX% to about in representing are total projected by have completed and with We accounts now of live be more of a volume XXXX. X year-end, XX our

Beyond Epic, practice with Flatiron throughout community integration networks XXXX. our with OncoEMR we integration large and active target several with have initiated EMR projects other have dates Health launch

pharma X. Now MRD on looking Slide at

business revenue. year, Pharma strong XX% had another prior quarter with regulatory Our of which included growth million milestone $X revenue in versus

main ODAC experience X We April significant momentum continue to recommendation in areas. following the

First, new studies.

These biopharma growth. from revenue have have future studies myeloma closed will new year-to-date. We support bookings increased new and seen XX investments

Second, endpoint. regulatory

expected, studies primary and signed X endpoint, recently As to being as is MRD primary X were have clonoSEQ endpoint. used that a We is XX secondary upgraded utilizing studies including myeloma increasingly multi a from now primary. as

successful dollar impact. milestone high clinical yield Some regulatory these of will payments upon million studies third, approval. And single-digit

to and the significance response. pharma MRD its patients of are educating highlight synergistic. utility key Pharma of a testing, about starting are measure physicians both companies and businesses clinical clinical as the mentioned, treatment As

long-term further on for achieved summary, treatment the In successes thriving fronts. in outlook bolster New adoption business. is enhance year our MRD-directed confidence will throughout if The the we regimens, approved, in MRD FDA multiple the clinic. have the

Immune Now X. Medicine turn to let's on Slide

and tumors as differentiated cancer possible. we working in develop many oncology, TCR-based Genentech continue R&D solid with cell We as autoimmunity. therapeutics to deliver immune-based with to therapy patients efforts high-impact In are advancing to

turnaround time Our and enhance of cell focus our to profile fully is cost, which personalized the will therapy reduce product. improve

an progress our patients will of identified a the high T unmet receptors multiple on sclerosis, time. In successfully with X with causing need. update and we subset indications at that Genentech autoreactive We medical in autoimmune cell appropriate autoimmunity, diabetes devastating provide likely disease with type several other are

completed successfully As antibody mentioned mouse we last quarter, immunization several campaigns.

testing antibodies that started these we quarter, making their properties. and attractive subset This a functionally of selected because of we

development build a a in by to first robust indication to nominate autoimmune our data autoimmune package year-end preclinical Our goal is lead antibody this and program. focus efforts

Now, walk over Kyle? financial results through to and to it I'm going pass updates. Kyle guidance to the

Thanks, Chad.

quarter representing year and X. grew from last versus the last test Total tests XX%, $XX.X XX% XX% same third $XX.X to increased quarter the delivered clinical including ASP respectively. ClonoSEQ Immune XX% revenue on million, with Let's the from million, contribution volume, prior start XX,XXX revenue with from period was of revenue with same period XX% XX,XXX year. in international, was to year. year XX% Medicine driven Genentech to by $X.X grew from from and amortization, in pharma revenue growth tests third XX% Immune industry for Medicine, quarter XX% Slide an and in MRD MRD the MRD decrease year's $X.X by increase sequencing ago, partially a services. million, upfront XXXX. prior Immune Medicine million recovery healthy grew took from pharma anticipated aged XX% year, versus reflecting the last biopharma year down offset claims pharma we X% a a U.S. related revenue XX% reserve in despite from X% prior pressures. in versus academic this charge and

of $XX.X driven given down represents from overhead of milestones production focus Genentech to mainly prior XX% lab in percentage more P&L, leverage, by leverage percentage of revenue decrease sequentially. drove biggest a lower with the representing functions contributor decline the Immune sequencing driving per our targeted This being significant increase This attributed continues the investments costs from inclusive sample. Total to labor and Moving of improvement to XX on for in once points million, which operating combined amortization, versus cost margin, which cost This want again in efficiencies Medicine. XX% and direct was mainly is highlight an be R&D was quarter, year. for quarter. last the year decrease I this lower X across the that points excludes spend

third by you improved can has also the bottom table from Medicine the see throughout to year sequentially a increased revenue (sic) EBITDA a spend. improved loss driven Immune XXXX in and in adjusted due and adjusted higher lower EBITDA ago. loss the in compared $XX.X reporting second loss and As company to both of segment million to million at quarter, EBITDA MRD the of adjusted operating a third quarter this spend. Total second -- ] reductions year the the of $X.X $XX.X was $XX.X operating of the slide, million million [ in revenue quarter

Finally, the for $XX.X to expense was quarter royalty financing was offset Net which loss more agreement our interest continues $X.X be OrbiMed million, interest with by from income. million. than

million mainly milestone guidance to previous end result million from Related are $XXX the our the This of to bottom increasing quarter, a X. revenue of now realized. Slide turning the our the Now performance $XXX year our to regulatory better-than-expected $XXX million to on MRD for third range full in million. full we to $XXX to is year, attributed

year the spend, full be million, and this range $XXX total total This between to unallocated due expect to is We sits the prior costs. restructuring MRD million. approximately within our $XXX business Immune $XXX excluding XX% for compares The million asset remaining onetime within corporate $XXX operating company and million Medicine. impairment to charges. XX% and Of approximately spend to of

burn and In our We XXXX. our $XXX over expect a previous be annual addition, now full $XXX represents the cash estimates burn. year versus of are million million expected approximately we XX% lowering reduction to

I enhance The the line year [ a of the approximately that, profile burn XX% approximately of from Chad. the remaining capital, expect strong corporate and costs. I XX% to while encouraged supporting strides the year. With the Immune we unallocated MRD business. and close making forward from due are our over ] hand to financial come am business to growth We our it I'll managing top to to back Medicine by is and this look

Kyle. Thanks,

delivering we've We are the promises on made.

clear up to driving back path business we like to on profitability open a MRD it focus execution to our operator to I'd while capital growth programs. With over Medicine continue and that, our are relentless targeted questions. turn advance with and the for Immune in allocation Our it disciplined

comes Our Instructions] with Cowen. question first [Operator from TD Brennan Dan

just Congrats Maybe the on gapfill the first final the on one quarter. price.

less the successful kind assuming of you're what or of can over a price? there? you're give And a us contracts in of So what's that now of range to in price targeting just $X,XXX if the terms maybe you for like some XXXX, of commercial converting higher you're realized outcomes these sense more

I'll Sure, to Dan. here. feel start jump with kind Kyle, of and free that, in

to So some that see of the This first, to in kind in extremely will a I of of to bleed the for take to long-term profile increase in. pleased business. close $XXX want terms margin say, just what of gapfill we're the price kind means time

me what And just so explain means. let that

XX%, of Medicare kind see of more it's So about new We'll for is fee-for-service overall XX% the fee-for-service patients. immediately that Medicare, impact Medicare about XX%.

an For is we on higher kind you if of renegotiate a uncontracted of some that overall, to timing But rate and of payers at but that uncertain. with go bring sooner, commercial in $X,XXX contracted at at above look to payers, expect more average patients $XXX XXXX $X,XXX which $X,XXX. that of to of in means and price XXXX, at point now ASP average the the we average to XXXX, some $X,XXX obviously increasing

ASP are Medicaid. what driven outstanding now. there's we this of initiatives some So is that expansion away to contracts mix with And right remaining $XXX And test the the the year, coverage, includes or of away I by grow in payer more we're put from that which from large of operational test ton per of shifting mentioned, we're payers. that -- enhancements kind on of place doing a closure going

during average -- this kind In of least payers. of how we that come will XXXX the per test $XX-plus through kind that expect from at addition, of new different and gapfill variety rate on anticipate works

can there we need will believe for -- at which out upside, payers. we but remaining a kind impact we So is of put believe the potential pace the do I We really do assess to this there.

just as the MRD exciting on maybe follow-up, then well. And just that's Great. pharma, as a

might the portend through and guide as of any MRD Just kind of that in studies what what's more assuming for baked pharma now And terms for in pharma? 'XX? for look you a kind of of XXXX a you bit your milestones? growth could just for beyond kind little activity funnel you Are walk of

you Kyle, that? take to want do

have it bookings. to just continue $XXX amount say relates -- mean roughly it. and say assumption associated I I a to I'd million is mean, in a funnel, there's through in ODAC milestones have that to backlog we QX, broadly, and as there. but dollar as catalyze we wouldn't risk-adjusted well the I to new big Yes. Relating to around going backlog,

think pretty profile. Not probably we year. I XXXX explicitly XXXX we're the ready growth this talk decent a to but So I into pharma achieved can confident guidance, think in what that's we assume rate similar to about

question with BTIG. comes from next Our Massaro Mark

guidance. Congrats on the the on I'll start quarter. Maybe

about in So did $X beat by you revenue. on million QX

to the some upper Recognizing the growth in either wanted contributed the that aware end the your of on the philosophy You you MRD that you pharma, thoughts strong have that of I to should get we seeing are of not through just did guide. or that? might Can maybe guidance any me be walk factors particulars just increase of?

the gave to of Obviously, us the milestone confidence QX low drove and increase of the range. happening kind derisk end Yes. an MRD in

didn't comfortable ASP the moving why we guess we charge took it previously not taking we're XQ, So mentioned I in further? forecast. I up. which

us one So can a I've out quarter-to-quarter subsequent in it's challenging. broken of that's this The probably is quarter. meaningfully mentioned is pushes or that the volatility. X the before, and it. it X about studies some to And record of next period, hurt pharma pretty rest

be potential just there's given hit given sorting we're we confident just we're in is it. still the hurricane softness and in putting other want confident out, and all guidance the some to But thing going guide. and that's just and can we're deliver for impact, The numbers through our prudent on the we so

as pharma, have you of just primary kind I I the you do about think or right say set, level be And did have so trials MM trials. great. a terms That's MRD XX endpoint? in clinical And numbers now of Okay. it on in might there to XX

to I'm if X primary So over to many think a we just or look out, years? trials for year get trying you even might say, how move a sense

clonoSEQ secondary kind converted of as including have primary, new multi recently have primary. now do and were We already Yes. and signed using a upgraded that been X XX as myeloma studies from to studies that X

highlight really seen so is One new of really studies seeing -- worth from And between XX nice of were XX of great of measurement good. some on and starting MRD new accelerated see. And response. is kind we in the increase number moving and there's myeloma, and get on these quickly to an of that pharma kind So just and of and It'd of areas. -- secondly, post-ODAC mentioned all in to a the of be companies for interplay approval then really to to hard management companies kind always new kind Of we've the kind the accelerate third, pharma which these it's where kind of importance in push. an kind we're studies, that and we opportunity the terms the think of great ODAC -- because clinical in decision, efforts trajectory of but as milestones we looking on are is of do in do of a do milestones, the treatment kind have as highlighting studies traction remarks, going studies impact business. from an see myeloma closed a X speculate, I continue of the kind put and obviously, of pathway. approvals but direct their to growth based on it clinical that's we -- there's in future the increase new And to year-to-date, then we've

kind our the And kind clinical bolsters of further so that of confidence in business.

convert expect and new to pool more be of milestones and kind new we many that we not direct So answer, of do on to us to that but milestones for contracts. access sign a outstanding able

that's one could last to any What more Maybe if from in, Great. can provide details one probability move the to sneak related about primary? hearing secondary success. pharma time granular clinical are you that. you things And the or specifically from the you're I hearing trial and/or some What about just potential key to primary? enrichment the the savings are this interest the of of to about if move

to primary approval a all, of utilized each Sure, eligible for MRD whether evaluate that note I endpoint. can independently company important with FDA it's the mean, as accelerated Mark. be needs whether trials first and their to are

in depend that of talking anticipating complete to endpoint potentially studies is the think that's have we're PFS endpoint those year significant a and some And X, seen being think study. evaluated it's That said, design years been takes setting. to be trial frame important last read with going depending also very get to years to time specifics by can X, are endpoint. on we've note. MRD on favorably in it XX now how companies therapy I X as will in have both an improvement which a I out regard the the MRD I certainly, the to to So it an that the the get first to over thing studies there clinical the from community, though, this a X And mean, primary received the defined.

very of could whether we're it feedback to getting utilized. interest evaluate the is So endpoint uniformly be that is primary a

treatment being program nuances setting certainly individual in time applied. on saved much be how development the each to can are distinctions there exactly However, and and the depending

with next Goldman Matt Our Sykes question Sachs. from comes

over there relative coverage market sort it's the ramp, a type to recurrent smaller of think how understanding that about just the got But in. I frequency other the the you given the the of aggressive markets potential just disease should disease. and like slightly testing one pivoting some smaller quarter. but we cell to of indication volume on of there. different and Maybe realize Congrats nature, characteristics it's you're mantle and of market,

insights for Thanks Yes. good the question. the underlying question and

around So mantle maybe the in indeed annual XX,XXX a around incidence bit prevalent It's patients, U.S. an smaller. cell patients. is X,XXX

dissimilar which volume note that But I also disease. So of will to today. our aggressive not is said, it's ALL, an XX%

long periods often course relapse years. As for over you noted, will They patients are of time. multiple of the monitored times

a course of might opportunities is so And an be a testing treatment also to therapy, for over are interventions, lifetime. The the line maintenance induction then there therapy, potentially consolidation myeloma some phase, there's of patient's and similar familiar of like transplanted indications the number where with clonoSEQ CAR-T. journey patients there's or including DLBCL, somewhat later there some you're other are

And a points, those an of so test, each opportunity much like play at role. MRD for malignancies other time there's to in we

that guidelines for for been not mantle Now example. have have myeloma, said, defined they like cell for been lymphoma

that monitoring varying frequencies being is these imaging to the in So is patients modality done. currently is on remains But which for be point treatment. imaging. depending periodically place, at a and there disease work in their that is done trajectory And the

as we disease time, And quite monitoring for think for assessment as well opportunity do both there's for so an response recurrence. that ongoing over

looks and then, Slide at quarter relative runway and how like on there you G&A, categories, areas where X, year-to-date. some at -- Great. of looking QX, some marketing, of you most to idea an G&A Could Kyle, to of upon us long to do expect color. And the kind just kind sort savings. of like Very you give that? helpful you were that just savings looking among for is R&D pretty last made it R&D, sales you impressive still last? where of year's And improve this progress the on did these runway just cost And the just

a marketing, story. I throughout I But sales it's handful Yes. think leverage made, done I'd the the restructurings and a mean, improvement we've we've year. say of

bit similar in made. org with story to as investments A We G&A. a in NovaSeq them. kind make flattened those Immune MRD, one left ops at of of lot quite bit we've a we reimbursement the larger savings. investments of of the a primarily initiatives to leverage. looking this drive in primarily but some have some the have We've There's out is targeted targeted the investments do function. result want Medicine. that R&D, We being

additional making as them, we'll for identify continue assess have any not think reductions we to opportunities and but So for opportunities look those in I savings, further plans we're to areas.

it, but this to org. again, there's lot about drive still our the and reduce And ops, don't think in leverage I'll to get. think didn't we continuing You overhead continue time. mention anything we additional flattening also I plans costs of I a any through some But to initiatives there leverage targeted will ask for at we're have

William Our comes from Brackmann next question Andrew Blair. with

Andrew This is want today. one for EMR on I integration. on ask Maggie to Boeye

sounds it the was like So in with there. Epic and quarter some there progress nice expanding accounts

integration talk some live? have do just you XXXX? altogether Flatiron, the can think EMR expanding accounts growth even you learnings in impact work that So there with to your expect you how volume this XX you about And further as now about of then

Thanks question, for the Maggie.

these to XX efficient. of leverage which first, terms able can going with best course implement learning, complete that accounts kind limited are substantially over testing that forward the I make some completed, the how helpful think are of the hit of degree with to that effectively to of We've resources, often sure we've to accounts gotten integrations in integrations standardizing So to understood we now more those ground running accounts. those we've be in the somewhat and tools the

of been the big is a already area to leverage increase to into tools time points. built focus of that's Epic standardization testing So

belt under what accounts for accounts integration. XX in more have to we're and that We been these our post looks better place growth understanding starting quarter, like have a seen than of a in X now with get

growth been accounts, a of for for those saw in accounts So they've live the that's least been X we X have live it's And that year. quarter-over-quarter for QX of X at -- QX, XX%. since

than quarter rest post integration. in see. growing pace still the to business, which now is that's faster They're a the their at great of third So

For couple went the were for accounts. our months, just where live previous right strong sort October, which in in the higher new we really of that the accounts been out to consistent of happy gate see experience month-over-month see growth growth of rates X has the past of with we

again, starting better to So look of the we're get what a view like. consistent patterns growth

that in-progress We have some of Epic, few quite order that 'XX a to proceeding utilized We be still XX And have in community of the integration of are a now. our that in about about integrated of platform year. another total networks. total we're accounts platform, an by community expect the the through XX% targeting or large integrations that's a volume completed will actually highly end end flow of whether Flatiron EMR this by

work are off XXXX. forward integrations we well community to in we -- and other as So we're with Flatiron, bringing the have looking kicked live as several that

just us think I be reduction it of just mentioned then just the opportunity looking last questions, and can the of should the progression update -- rollout thinking about one on NovaSeq into just XXXX there here? you we how the on And on was but just Great. for COGS of

lot making of We're progress, of lot headway. a a Yes.

that plans the is launch and quarter Our well, still it currently. third assuming in pointing for of everything are everything to goes in direction XXXX,

a our profile believe margin there. just business. that And from expanding XX to then of As the profile X% grow, gross And profile trajectory think for to improvement we are annualized, to of in at, in it where get continue long-term MRD we volumes as depending kind that. X% you XX% the the financial get on volumes we can first probably months to reiterates margin relates I profile, can it margin think

Nam Scotiabank. Our Ji next question comes from with Sung

Rosenbaum the following on Ji. for how Corey if year? this is Sung much of you us remind amortization This remains, Could Genentech any,

I around million. probably $XX exit $XX to million believe with we'll

And a XX-XX to MRD best Got about is around Immune ] spend faster next and between than [ way think year grow still total for OpEx the continues look and pace you. we the at Medicine as Immune to next year? MRD Medicine, to

is I provide the in we're of We'll kind guidance constrain February. Immune kind to What of updated spend. say Medicine can looking

a it lower be on will So percentage basis.

next Stanley. with question Morgan Tejas comes Savant from Our

] is on Jason This [ Tejas. quarter. the on for Congratulations

So behavioral some from where maybe diagnostics space off, no cover longer in health. a news player was would recent large announced starting just the UnitedHealth for that multi-gene there they panels

different just stringent recently challenges wondering, I payers just genetic your So how think biomarker faced of these more some the you on do authorization on dragging have obviously, build about broadly, perhaps their weighing was testing costs, you have fee more enthusiasm spiraling to or a portfolio, prior private for but due on rollouts.

question. spend lot it's -- XXst background, with about test think I Board for a brings for And it payer of No, looking patients. on Coalition I broadly, a the I'm good say as and landscape the what more time private it's one, of clonoSEQ, Century the side. our on both just would We and to on just for the for Board sit I at Medicine. our respect a and the this, government side And value payer

the consistently health research overall the that's the tests other is the across people's recognized I'm that your by it we both reimbursement I you and it making the go the and and kind test, to value think relates system of been in on pricing those the and and clonoSEQ Medicare savings look value and private to speaking really directly profiles to we And don't role And -- sure so at and outcomes I government just as health play payers that into the economics a all of about don't really of of brings and factors value. if kind by comment or -- general. test board.

and is the to rapidly provides for off that of that the us example maintenance taking in a great $XXX,XXX of patient one able that, be like savings to use myeloma, As you expanding case at test therapy that's is if multi year. are patients look subsequent therapies the for confidence very multi name but take you won't a X clinician know the MRD in to to readings per maintenance give of off names, myeloma -- over I expensive

year It's is to being a And say, a business, that that paid so is we're the that and payer continue then investing brings and progress want value making continue making challenges we something we in focus a side that But to do side, that, in a heavy we're to general, the both costs per in. and when and you're to we an CEO all that test in faced rate operations. it on best that sure which that the $X,XXX that want sure at I on we're diagnostic would and people with collecting this emphasis about we a to we're on where such mean is cash, have getting payers reimbursement reimbursement, high talking area why in to that promote. I get contracting that

And it. their they narrowing follow-up. maybe some There was just a Roche, that pipeline. of news Got in quick September a then announced XX%

with So after announcement, this any Genentech? you just have to wondering, partnership impact your sensed

question. Great

and at Roche announced we that assured can their that partnership, oncology this also our does have all have us impact As an on time. they comment that's reorganizing that, not on division, were research they

may day. does I'm time. disconnect. now this and showing conclude good Everyone, you. Thank at no This the you further questions program,